Drug Trial Radar · NCT02099240
Patients Response to Early Switch To Oral:Osteomyelitis Study
Last checked: Nov 19, 2026Latest source record: Apr 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Mar 6, 2014
Primary completion
Nov 7, 2018
Study completion Nov 7, 2018
Sponsor
- Lead sponsor
- Julio RamirezAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Louisville
- First posted
- Mar 28, 2014
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Conditions
- Osteomyelitis
Interventions
oral antibioticsDrug
intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
intravenous antibioticsProcedure
intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical FailuresTime frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Louisville
Louisville, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.